

RE: SLS-005-302: A Double-Blind, Randomized, Placebo-Controlled Trial to Assess Safety and Efficacy of SLS-005 (Trehalose Injection, 90.5 mg/mL for Intravenous Infusion) for the Treatment of Adults with Spinocerebellar Ataxia.

You are being invited to take part in the STRIDES study, a clinical research study of an investigational new drug (not approved as a marketed product) to treat Spinocerebellar Ataxia (SCA). This study is being sponsored by Seelos Therapeutics Inc. and the name of this investigational new drug is SLS-005 (trehalose). The study drug is a naturally occurring sugar which is used in small amounts in food products, cosmetics, and other drugs. Research studies of the study drug in cells, animals, and humans with SCA and other conditions, show that higher doses may help to clear out damaging molecules in cells in diseases such as SCA. The study drug is administered once a week for 52 consecutive weeks by an intravenous (IV) infusion to make sure enough trehalose reaches the cells of the brain and spinal cord.

STRIDES is a phase 2b/3 study planning to enroll up to 245 participants between the ages of 18 and 75 with SCA type-3. Participants will be recruited from up to 30 centers globally, approximately 7 centers will be in the United States. 200 patients will be assigned study drug (SLS-005) at a dose of 0.75 g/kg or placebo (a study drug look-alike, but it contains no active ingredients). An additional 45 patients will be assigned study drug (SLS-005) at a dose of 0.5 g/kg or placebo. Study participation will span 56 weeks; 2 weeks study screening to determine your eligibility for the study, 52 weeks of treatment with the study drug, and ending with a safety follow-up visit 2 weeks after the last study drug administration. You may be reimbursed for reasonable expenses such as mileage and parking for travel associated with each study visit.

To qualify for the trial, you must be a man or woman between 18 and 75 years old with a clinical diagnosis of SCA 3 with genetic confirmation, a body mass index between 18 kg/m² and 35 kg/m², and you cannot be pregnant or breastfeeding. Patients who have received prior treatment with SLS-005, any other IV formulation, or with a known hypersensitivity to trehalose will not be eligible for the study. Additionally, patients with any of the following conditions will not be eligible for participation:

- Current diagnosis and/or healthcare professional recommended treatment (medication and/or diet) of diabetes mellitus type 1 or type 2
- Chronic liver disease including hepatitis B; Hepatitis C unless successful curative treatment is documented; human immunodeficiency virus (HIV) infection
- Prior history of liver induced injury

The following US study centers are currently planning on participating in the STRIDES study:

Principal Investigator and Study Center	Location	Recruitment Contact	Recruitment Contact Details
Dr. Susan Perlman - University of California Los	300 UCLA Med Plaza Suite B200, Los Angeles, CA 90095	Aaron Fisher	E: Adfisher@mednet.ucla.edu T: +1 (310) 206-8153

Angeles (UCLA)			
Dr. Vikram Shakkottai - University of Texas Southwestern Medical Center	5323 Harry Hines Blvd, Dallas, TX 75390	Pheba E. Sunny	E: phebaelizabeth.sunny@utsouthwestern.edu T: +1 (469) 625-5508
Dr. Theresa Zesiewicz - University South Florida	12901 Bruce B Downs Blvd, MDC 55, Tampa, FL 33612	Lucretia Campbell and Paige Graham	E: lcampbel@usf.edu E: paigegraham@usf.edu T: +1 (813) 974-5633 T: +1 (813) 974-4453
Dr. Patricia Greenstein - Harvard Medical School - Beth Israel Deaconess Medical Center (BIDMC)	375 Longwood Ave Suite 3, Boston, MA 02215	Dr. Patricia Greenstein	E: pgreenst@bidmc.harvard.edu T: +1 (617) 667-3176
Dr. Trevor Hawkins – UC Health Neurosciences Center - Anschutz Medical Campus	12631 E. 17th Ave. Academic Office 1, Room 5212 Aurora, CO 80045	Ying Liu	E: ying.3.liu@cuanschutz.edu T: 303-724-8288

Please reach out to the recruitment contact listed in the table above for additional information about the study.

If you have a family history of SCA3 but have not undergone genetic testing, you may be eligible for the National Ataxia Foundation’s free virtual Genetic Counseling and Testing Program. The Genetic Counseling and Testing Program is available to a person who is at-risk for SCA1, SCA2, and/or SCA3 because they have a family member with a confirmed genetic diagnosis. Participants must live in the United States, be 18 years of age or older, and become a free member of NAF to participate. You do not need a referral from a physician to participate. To determine if you are eligible and to enroll in the program, contact NAF by emailing research@ataxia.org.

Thank you for your time and consideration.

The National Ataxia Foundation